Swiss National Bank decreased its holdings in Alkermes plc (NASDAQ:ALKS – Free Report) by 0.8% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 313,800 shares of the company’s stock after selling 2,400 shares during the quarter. Swiss National Bank’s holdings in Alkermes were worth $8,783,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. O Shaughnessy Asset Management LLC raised its position in shares of Alkermes by 21.2% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 11,976 shares of the company’s stock valued at $324,000 after buying an additional 2,097 shares in the last quarter. Advisors Asset Management Inc. raised its position in shares of Alkermes by 19.6% in the 1st quarter. Advisors Asset Management Inc. now owns 29,886 shares of the company’s stock valued at $809,000 after buying an additional 4,891 shares in the last quarter. Lazard Asset Management LLC raised its position in shares of Alkermes by 655.0% in the 1st quarter. Lazard Asset Management LLC now owns 77,102 shares of the company’s stock valued at $2,087,000 after buying an additional 66,890 shares in the last quarter. Bayesian Capital Management LP acquired a new position in shares of Alkermes in the 1st quarter valued at approximately $333,000. Finally, Tidal Investments LLC acquired a new position in shares of Alkermes in the 1st quarter valued at approximately $441,000. Institutional investors and hedge funds own 95.21% of the company’s stock.
Alkermes Trading Up 2.0 %
ALKS opened at $29.36 on Tuesday. Alkermes plc has a fifty-two week low of $22.22 and a fifty-two week high of $32.88. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.45 and a quick ratio of 3.03. The firm has a market capitalization of $4.75 billion, a price-to-earnings ratio of 15.06, a PEG ratio of 0.96 and a beta of 0.47. The company’s 50 day moving average price is $27.92 and its two-hundred day moving average price is $26.42.
Insiders Place Their Bets
Wall Street Analyst Weigh In
Several equities analysts have recently commented on ALKS shares. JPMorgan Chase & Co. dropped their target price on shares of Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Stifel Nicolaus raised shares of Alkermes from a “hold” rating to a “buy” rating and lifted their price target for the company from $25.00 to $36.00 in a report on Tuesday, November 5th. HC Wainwright reaffirmed a “neutral” rating and set a $37.00 price target on shares of Alkermes in a report on Friday, October 25th. Cantor Fitzgerald decreased their price target on shares of Alkermes from $48.00 to $43.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. Finally, The Goldman Sachs Group decreased their price target on shares of Alkermes from $32.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.42.
View Our Latest Stock Report on Alkermes
Alkermes Profile
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
See Also
- Five stocks we like better than Alkermes
- Investing in Construction Stocks
- Abacus Life’s CEO on Cracking the Code of Longevity Returns
- Are Penny Stocks a Good Fit for Your Portfolio?
- Elon Musk and Trump Push for Self-Driving Cars: 3 Stocks to Gain
- About the Markup Calculator
- Discover the 3 Best Performing Stocks That Went Public in 2024
Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes plc (NASDAQ:ALKS – Free Report).
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.